Who
Judith L. Swain
Director
Company insider
Files Form 4 as: Director, Lexicon Pharmaceuticals; Director, Prometheus Biosciences.
In numbers
- Trades disclosed
- 58
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 24 Sep 2007
- Last trade
- 3 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,714 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,478 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,714 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,478 at $0.00 | filing |
| 3 Jun 2025filed 3 Jun 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —103,806 at $0.00 | filing |
| 3 Jun 2025filed 3 Jun 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —89,312 at $0.00 | filing |
| 13 May 2025filed 13 May 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —36,810 at $0.00 | filing |
| 13 May 2025filed 13 May 2025 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —36,810 at $0.00 | filing |
| 13 May 2024filed 13 May 2024 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,906 at $0.00 | filing |
| 13 May 2024filed 13 May 2024 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,810 at $0.00 | filing |
| 28 Apr 2024filed 29 Apr 2024 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,032 at $0.00 | filing |
| 28 Apr 2024filed 29 Apr 2024 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,032 at $0.00 | filing |
| 16 Jun 2023filed 16 Jun 2023 | Prometheus Biosciencesoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 16 Jun 2023filed 16 Jun 2023 | Prometheus Biosciencesoption or derivative | SEC FORM 4 Code D | —20,500 | filing |
| 16 Jun 2023filed 16 Jun 2023 | Prometheus Biosciences | SEC FORM 4 Code D | —2,071 | filing |
| 21 May 2023filed 22 May 2023 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,302 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.